Showing 3531-3540 of 7549 results for "".
- Timber's Topical Isotretinoin Gets Breakthrough Therapy Designation for CIhttps://practicaldermatology.com/news/timbers-topical-isotretinoin-gets-breakthrough-therapy-designation-for-ci/2461217/TMB-001, a topical isotretinoin formulated using patented IPEG™ delivery system from Timber Pharmaceuticals, Inc. has been granted Breakthrough Therapy designation by FDA for the treatment of congenital ichthyosis (CI). Timber is developi
- Apyx Medical Corporation Receives FDA 510(k) Clearance for Renuvion Handpiecehttps://practicaldermatology.com/news/apyx-medical-corporation-receives-fda-510k-clearance-for-renuvion-handpiece/2461216/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to
- Verrica Receives Complete Response Letter from FDA for NDA for VP-102https://practicaldermatology.com/news/verrica-receives-complete-response-letter-from-fda-for-nda-for-vp-102/2461214/The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc.'s New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). According to the company, the only deficiency listed in the CRL was related to the deficiencies
- Global Dermatology Coalition Launcheshttps://practicaldermatology.com/news/global-dermatology-coalition-launches/2461212/The Global Dermatology Coalition, a patient-led, multi-stakeholder group of organizations, has launched during the 75th World Health Assembly in Geneva. The Global D
- Crown to Acquire Aesthetic Product Portfolio from Eclipsehttps://practicaldermatology.com/news/crown-to-acquire-aesthetic-product-portfolio-from-eclipse/2461208/Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions. "We
- June Risser Named General Manager of Premium Skincare Business Unit at Crown Laboratorieshttps://practicaldermatology.com/news/june-risser-named-general-manager-of-premium-skincare-business-unit-at-crown-laboratories/2461207/June Risser is Crown Laboratories, Inc.’s new General Manager of Premium Skincare. She will lead the global business unit which includes StriVectin and Vita Liberata, and she will hold a position on the Executive Leadership Team. Prior to Crown, she was General Man
- CHMP Recommends Approval of Lilly and Incyte's Olumiant for Severe AAhttps://practicaldermatology.com/news/chmp-recommends-approval-of-lilly-and-incytes-olumiant-for-severe-aa/2461204/The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly and Company and Incyte’s Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA). This opinion marks the fir
- Nutrafol Launches Collagen Infusionhttps://practicaldermatology.com/news/nutrafol-launches-collagen-infusion/2461203/Collagen Infusion from Nutrafol is now available for health care providers to purchase on
- The Skin Cancer Foundation Raises $625,000 For Skin Cancer Education Programs at Annual Galahttps://practicaldermatology.com/news/the-skin-cancer-foundation-raises-625000-for-skin-cancer-education-programs-at-annual-gala/2461200/The Skin Cancer Foundation Champions for Change Gala raised $625,000 in support of the organization’s educational campaigns, community programs and research initiatives. More than 300 guests attended the event, including Skin Cancer Foundation donors, industry and physician
- Cynosure Scores $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://practicaldermatology.com/news/cynosure-scores-60-million-follow-on-investment-from-clayton-dubilier-rice/2461199/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its customers that